Compare EIC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | XBIT |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 66.8M |
| IPO Year | 2018 | 2015 |
| Metric | EIC | XBIT |
|---|---|---|
| Price | $9.42 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.63 | N/A |
| AVG Volume (30 Days) | ★ 92.1K | 43.6K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.17 | $2.09 |
| 52 Week High | $13.55 | $3.44 |
| Indicator | EIC | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 24.23 | 40.04 |
| Support Level | $9.33 | N/A |
| Resistance Level | $10.14 | $2.48 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 2.67 | 15.38 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.